GW766994   Click here for help

GtoPdb Ligand ID: 9680

Synonyms: GSK766994 | GW-766994
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GW766994 is an investigational CCR3 antagonist [5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 96.69
Molecular weight 450.12
XLogP 2.39
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(NCc1ccc(cc1)C(=O)N)NCC1OCCN(C1)Cc1ccc(c(c1)Cl)Cl
Isomeric SMILES O=C(NCc1ccc(cc1)C(=O)N)NC[C@H]1OCCN(C1)Cc1ccc(c(c1)Cl)Cl
InChI InChI=1S/C21H24Cl2N4O3/c22-18-6-3-15(9-19(18)23)12-27-7-8-30-17(13-27)11-26-21(29)25-10-14-1-4-16(5-2-14)20(24)28/h1-6,9,17H,7-8,10-13H2,(H2,24,28)(H2,25,26,29)/t17-/m1/s1
No information available.
Summary of Clinical Use Click here for help
GW766994 has completed Phase 2 clinical trial (NCT01160224) in patients with mild-moderate asthma who have high sputum eosinophilia. Safety and efficacy in early clinical trial are reported by Neighbour et al. (2014) [4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01160224 Oral GW766944 (Oral CCR3 Antagonist) Phase 2 Interventional GlaxoSmithKline